Form 4: Akero Therapeutics CSO Donates 37,100 Shares

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, gifted 37,100 shares of common stock to a donor-advised fund.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), reported a disposition of common stock.
• On November 17, 2025, Mr. Rolph gifted 37,100 shares of Akero Therapeutics common stock.
• The shares were donated as a gift to a donor-advised fund, with a transaction price of $0 per share.
• Following this transaction, Mr. Rolph beneficially owns 129,471 shares of Akero Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: Neutral, as it represents a philanthropic gift of shares by an insider rather than a transaction driven by market sentiment or company performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction filing (Form 4) reporting a personal disposition of shares by an executive, which is common across all industries and does not reflect specific industry trends or competitive dynamics.

Stakeholder Impact

• Minor reduction in direct beneficial ownership by a key executive, which slightly alters the insider ownership structure.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Transaction, Stock Gift, Timothy Rolph, Chief Scientific Officer, Beneficial Ownership